IgG antibodies are crucial for protection against invading pathogens. A highly conserved N-linked glycan within the IgG-Fc tail, essential for IgG function, shows variable composition in humans. Afucosylated IgG variants are already used in anti-cancer therapeutic antibodies for their elevated activity through Fc receptors (FcγRIIIa). Here, we report that afucosylated IgG (~6% of total IgG in humans) are specifically formed against enveloped viruses but generally not against other antigens. This mediates stronger FcγRIIIa responses, but also amplifies brewing cytokine storms and immune-mediated pathologies. Critically ill COVID-19 patients, but not those with mild symptoms, had high levels of afucosylated IgG antibodies against SARS-CoV-2, amplifying pro-inflammatory cytokine release and acute phase responses. Thus, antibody glycosylation plays a critical role in immune responses to enveloped viruses, including COVID-19.

27IgG antibodies are crucial for protection against invading pathogens. A highly conserved N-28 linked glycan within the IgG-Fc-tail, essential for IgG function, shows variable composition in 29 humans. Afucosylated IgG variants are already used in anti-cancer therapeutic antibodies for 30 their elevated binding and killing activity through Fc receptors (FcγRIIIa). Here, we report that 31 afucosylated IgG which are of minor abundance in humans (~6% of total IgG) are specifically 32 formed against surface epitopes of enveloped viruses after natural infections or 33 immunization with attenuated viruses, while protein subunit immunization does not elicit 34 this low fucose response. This can give beneficial strong responses, but can also go awry, 35 resulting in a cytokine-storm and immune-mediated pathologies. In the case of COVID-19, 36 the critically ill show aggravated afucosylated-IgG responses against the viral spike protein. In 37 contrast, those clearing the infection unaided show higher fucosylation levels of the anti-38 spike protein IgG. Our findings indicate antibody glycosylation as a potential factor in 39 inflammation and protection in enveloped virus infections including COVID-19.40Main Text: 41 Antibodies have long been considered functionally static, mostly determined by their isotype 42 and subclass. The presence of a conserved N-linked glycan at position 297, in the so called 43 constant Fc-domain of IgG, is essential for effector functions (1-3). Moreover, it is now 44 generally accepted that the composition of this glycan is highly variable and has functional 45 consequences (2-4). This is especially true for the core fucose attached to the Fc glycan. The 46 discovery that IgG variants without core fucosylation cause elevated antibody dependent 47 cellular cytotoxicity (ADCC), via increased IgG-Fc-receptor IIIa (FcγRIIIa) affinity (5, 6), 48 resulted in next-generation glyco-engineered monoclonal antibodies (mAb) without core 49 fucosylation for targeting tumors (7). 50Generally, changes in the Fc glycans are associated with age, sex and autoimmune diseases 51 (8). Serum IgG are highly fucosylated at birth and slightly decrease to ~94% fucosylation at 52 adulthood (9). Until now, no strong clues on how IgG core fucosylation is controlled have 53 come forward. 54 We have previously observed that alloantibodies against red blood cells (RBC) and platelets 55 show remarkably low IgG-Fc-fucosylation in most patients, even down to 10% in several 56 cases (10-12), whereas the overall serum IgG Fc-fucosylation show consistently normal high 57 levels. Moreover, we have reported the lowered IgG-Fc fucosylation to be one of the factors 58 determining disease severity in pregnancy associated alloimmunizations, resulting in 59 excessive thrombocytopenia's and blood cell destruction when targeted by afucosylated 60 antibodies (11)(12)(13). In addition to the specific afucosylated-IgG response against platelets 61 and RBC antigens, this response has also been identified against HIV and Dengue virus (...

No abstract

No abstract

The onset of severe SARS-CoV-2 infection is characterized by the presence of afucosylated IgG1 responses against the viral spike (S) protein, which can trigger exacerbated inflammatory responses. Here, we studied IgG glycosylation after BNT162b2 SARS-CoV-2 mRNA vaccination to explore whether vaccine-induced S protein expression on host cells also generates afucosylated IgG1 responses. SARS-CoV-2 naive individuals initially showed a transient afucosylated anti-S IgG1 response after the first dose, albeit to a lower extent than severely ill COVID-19 patients. In contrast, previously infected, antigen-experienced individuals had low afucosylation levels, which slightly increased after immunization. Afucosylation levels after the first dose correlated with low fucosyltransferase 8 (FUT8) expression levels in a defined plasma cell subset. Remarkably, IgG afucosylation levels after primary vaccination correlated significantly with IgG levels after the second dose. Further studies are needed to assess efficacy, inflammatory potential, and protective capacity of afucosylated IgG responses.One sentence summaryA transient afucosylated IgG response to the BNT162b2 mRNA vaccine was observed in naive but not in antigen-experienced individuals, which predicted antibody titers upon the second dose.

No abstract

No abstract